Maxwell Greene, MD
Neurology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 18
- 4 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
18 plans · 4 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Greene’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
18 of 18 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A152405 · Current
Licensed to practise in California · since 2017 · expires 2029-02-28 · Jefferson Medical College of Thomas Jefferson University.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$60,834
Medicare paid this office $60,834 for 270 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 108 | $17,767 | $123 |
| Long return visit (40+ min) | 46 | $11,178 | $153 |
| New patient visit (60+ min) | 33 | $5,225 | $158 |
| Muscle electrical test | 67 | $3,222 | $40 |
| Nerve test | 34 | $3,085 | $91 |
See all 13 services
| Long return visit (40+ min) | 108 | $17,767 | $123 |
| Long return visit (40+ min) | 46 | $11,178 | $153 |
| New patient visit (60+ min) | 33 | $5,225 | $158 |
| Muscle electrical test | 67 | $3,222 | $40 |
| Nerve test | 34 | $3,085 | $91 |
| Nerve test | 25 | $3,006 | $120 |
| Nerve test | 14 | $2,370 | $169 |
| Nerve test | 11 | $1,574 | $143 |
| Muscle electrical test | 63 | $1,403 | $17 |
| Return visit (30+ min) | 12 | $1,395 | $107 |
| Nerve test | 13 | $867 | $67 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 34 | $562 | $15 |
| Muscle electrical test | 12 | $402 | $34 |
Who their Medicare patients are
270 Original Medicare patients in 2024. Average age 73 · Under 65 13% · 85 and older 6% · Women 46% · Also on Medicaid 16% · Health risk score 1.51. At or below the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 75% · Coronary heart disease 34% · Diabetes 29% · Atrial fibrillation 23% · Depression 23% · Heart failure 20% · Chronic kidney disease 20% · Cancer 15% · COPD 13% · Stroke 11% · Dementia 7%.
The office billed $1,119,479, Medicare allowed $80,540 and paid $60,834; for 697 services of 34 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 270 | 697 | 73 | 1.51 | $1,119,479 | $60,834 |
| 2023 | 262 | 673 | 73 | 1.60 | $1,066,899 | $60,406 |
| 2022 | 227 | 582 | 73 | 1.64 | $721,223 | $51,175 |
| 2021 | 193 | 663 | 72 | 1.47 | $873,420 | $63,760 |
| 2020 | 112 | 297 | 71 | 1.31 | $457,577 | $24,211 |
| 2019 | 88 | 292 | 70 | 1.96 | $140,688 | $21,726 |
| 2018 | 93 | 198 | 69 | 2.23 | $99,597 | $15,342 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Long return visit (40+ min) | 119 | $24,509 | $130 |
| New patient visit (60+ min) | 54 | $8,609 | $159 |
| Nerve test | 40 | $4,916 | $123 |
| Muscle electrical test | 62 | $3,025 | $43 |
| Nerve test | 16 | $2,964 | $174 |
| Nerve test | 27 | $2,652 | $98 |
| Return visit (30+ min) | 24 | $2,281 | $88 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 17 | $2,033 | $120 |
| Muscle electrical test | 71 | $1,844 | $17 |
| Short return visit (20+ min) | 12 | $793 | $61 |
| Muscle electrical test | 11 | $381 | $35 |
2022: 8 services
| Long return visit (40+ min) | 131 | $24,725 | $115 |
| New patient visit (60+ min) | 54 | $7,605 | $141 |
| Nerve test | 20 | $2,514 | $120 |
| Nerve test | 14 | $2,488 | $178 |
| Return visit (30+ min) | 28 | $2,289 | $79 |
| Nerve test | 21 | $2,122 | $101 |
| Muscle electrical test | 42 | $1,856 | $43 |
| Muscle electrical test | 57 | $1,575 | $17 |
2021: 8 services
| Long return visit (40+ min) | 110 | $30,376 | $128 |
| New patient visit (60+ min) | 76 | $12,127 | $160 |
| Nerve test | 29 | $3,643 | $126 |
| Nerve test | 15 | $2,782 | $174 |
| Nerve test | 26 | $2,538 | $98 |
| Muscle electrical test | 48 | $2,212 | $40 |
| Muscle electrical test | 68 | $1,813 | $17 |
| Return visit (30+ min) | 20 | $1,720 | $82 |
2020: 9 services
| Long return visit (40+ min) | 32 | $4,386 | $107 |
| New patient visit (60+ min) | 27 | $4,198 | $155 |
| Muscle electrical test | 51 | $2,706 | $44 |
| New patient visit (45+ min) | 22 | $2,615 | $119 |
| Nerve test | 12 | $1,598 | $123 |
| Nerve test | 15 | $1,546 | $103 |
| Return visit (30+ min) | 18 | $1,404 | $74 |
| Nerve test | 14 | $1,079 | $77 |
| Muscle electrical test | 30 | $761 | $18 |
2019: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 27 | $8,327 | $64 |
| Long return visit (40+ min) | 33 | $5,218 | $95 |
| New patient visit (60+ min) | 13 | $1,725 | $133 |
| Extended office or other outpatient service, first hour | 13 | $1,515 | $108 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,086 | $99 |
| Hospital discharge day management, 30 minutes or less | 12 | $789 | $66 |
| Test to measure expiratory airflow and volume | 14 | $158 | $7 |
2018: 4 services
| Long return visit (40+ min) | 32 | $5,282 | $98 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $1,965 | $63 |
| New patient visit (60+ min) | 11 | $1,495 | $136 |
| Test to measure expiratory airflow and volume | 15 | $158 | $7 |
Medicaid work
$1,044 in 2024
Medicaid paid $1,044 for 14 billed services this clinician did in 2024, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Muscle electrical test | 14 | $1,044 |
| 2024 | 14 | 1 | 14 | $1,044 |
| 2019 | 20 | 1 | 15 | $0 |
| 2018 | 29 | 1 | 14 | $540 |
See the largest Medicaid services in earlier years
2019
| OFF/OP EST MAY X REQ PHY/QHP | 20 | $0 |
2018
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 29 | $540 |
Drugs they prescribed that Part D paid
$1,454,268
Pharmacies billed $1,454,268 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 2% of their Part D prescriptions (11 of 664) in 2024. Above the middle of the specialty; the typical neurology clinician is at 0%.
540 generic and 124 brand-name prescriptions · $1,454,268 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Radicava Ors | None | 68 | $903,298 | $13,284 |
| Relyvrio | None | 18 | $215,997 | $12,000 |
| Gamunex-C | Immune globulin | 17 | $97,432 | $5,731 |
| Riluzole | None | 71 | $11,138 | $157 |
| Modafinil | None | 18 | $5,402 | $300 |
See all 17 drugs
| Radicava Ors | None | 68 | $903,298 | $13,284 |
| Relyvrio | None | 18 | $215,997 | $12,000 |
| Gamunex-C | Immune globulin | 17 | $97,432 | $5,731 |
| Riluzole | None | 71 | $11,138 | $157 |
| Modafinil | None | 18 | $5,402 | $300 |
| Gabapentin | None | 84 | $2,099 | $25 |
| Mycophenolate Mofetil | None | 16 | $1,513 | $95 |
| Lidocaine | None | 11 | $846 | $77 |
| Baclofen | None | 17 | $816 | $48 |
| Tramadol | None | 11 | $740 | $67 |
| Pregabalin | None | 34 | $702 | $21 |
| Nortriptyline | None | 34 | $581 | $17 |
| Carbidopa-Levodopa | None | 43 | $535 | $12 |
| Mirtazapine | None | 11 | $397 | $36 |
| Duloxetine | None | 20 | $311 | $16 |
| Prednisone | None | 29 | $90 | $3 |
| Tamsulosin | None | 13 | $37 | $3 |
Year by year
| 2024 | 664 | 102 | 2% (11) | 19% | $1,454,268 |
| 2023 | 545 | 90 | None | 26% | $1,992,967 |
| 2022 | 695 | 82 | None | 10% | $1,116,455 |
| 2021 | 347 | 66 | None | 12% | $550,066 |
| 2020 | 102 | 38 | 0% (0) | 14% | $10,609 |
| 2019 | 219 | 48 | None | 19% | $160,889 |
| 2018 | 125 | 35 | 0% (0) | 20% | $67,493 |
| 2015 | 80 | 15 | 0% (0) | 19% | $84,738 |
| 2014 | 126 | 16 | 0% (0) | 11% | $37,705 |
| 2013 | 88 | 17 | None | 15% | $29,721 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 15 drugs
| Radicava Ors | None | 60 | $836,566 | $13,943 |
| Relyvrio | None | 42 | $496,254 | $11,816 |
| Gammaplex | Immune globulin | 20 | $454,562 | $22,728 |
| Gamunex-C | Immune globulin | 16 | $133,552 | $8,347 |
| Riluzole | None | 42 | $7,730 | $184 |
| Baclofen | None | 25 | $1,751 | $70 |
| Carbidopa-Levodopa | None | 37 | $1,288 | $35 |
| Mycophenolate Mofetil | None | 19 | $1,120 | $59 |
| Pregabalin | None | 24 | $1,016 | $42 |
| Gabapentin | None | 43 | $969 | $23 |
| Duloxetine | None | 32 | $799 | $25 |
| Nortriptyline | None | 21 | $694 | $33 |
| Oxybutynin Chloride | None | 12 | $595 | $50 |
| Tamsulosin | None | 16 | $165 | $10 |
| Prednisone | None | 23 | $123 | $5 |
2022: 18 drugs
| Gammaplex | Immune globulin | 17 | $508,522 | $29,913 |
| Octagam | Immune globulin | 23 | $293,278 | $12,751 |
| Radicava Ors | None | 11 | $155,183 | $14,108 |
| Riluzole | None | 75 | $42,109 | $561 |
| Modafinil | None | 18 | $9,509 | $528 |
| Pregabalin | None | 65 | $2,736 | $42 |
| Gabapentin | None | 60 | $2,091 | $35 |
| Mycophenolate Mofetil | None | 29 | $1,826 | $63 |
| Mirtazapine | None | 18 | $1,584 | $88 |
| Baclofen | None | 40 | $1,558 | $39 |
| Atropine Sulfate | None | 19 | $1,448 | $76 |
| Nortriptyline | None | 40 | $912 | $23 |
| Prednisone | None | 55 | $779 | $14 |
| Duloxetine | None | 29 | $489 | $17 |
| Ropinirole | None | 22 | $439 | $20 |
| Phenytoin | None | 11 | $391 | $36 |
| Trazodone | None | 15 | $178 | $12 |
| Carbidopa-Levodopa | None | 13 | $128 | $10 |
2021: 10 drugs
| Octagam | Immune globulin | 12 | $471,559 | $39,297 |
| Modafinil | None | 13 | $13,341 | $1,026 |
| Riluzole | None | 50 | $8,212 | $164 |
| Gabapentin | None | 42 | $1,788 | $43 |
| Baclofen | None | 20 | $1,473 | $74 |
| Mirtazapine | None | 13 | $1,421 | $109 |
| Pregabalin | None | 19 | $940 | $49 |
| Nortriptyline | None | 36 | $431 | $12 |
| Phenytoin | None | 14 | $424 | $30 |
| Prednisone | None | 18 | $244 | $14 |
2020: 2 drugs
| Gabapentin | 22 | $551 | $25 |
| Nortriptyline | 19 | $283 | $15 |
2019: 5 drugs
| Riluzole | 31 | $10,383 | $335 |
| Carbidopa-Levodopa | 17 | $1,172 | $69 |
| Baclofen | 13 | $279 | $21 |
| Prednisone | 11 | $129 | $12 |
| Sertraline | 12 | $88 | $7 |
2018: 3 drugs
| Riluzole | 18 | $6,872 | $382 |
| Amantadine | 15 | $776 | $52 |
| Atropine Sulfate | 14 | $570 | $41 |
2015: 2 drugs
| Levetiracetam | 13 | $666 | $51 |
| Lamotrigine | 17 | $215 | $13 |
2014: 3 drugs
| Lamotrigine | 33 | $369 | $11 |
| Oxcarbazepine | 11 | $308 | $28 |
| Nortriptyline | 11 | $84 | $8 |
2013: 1 drug
| Lamotrigine | 12 | $192 | $16 |
Money from drug and device companies
$93 in 2025
| 2025 | 1 | 6 | None | $93 |
| 2019 | 1 | 1 | None | $18 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Ucb | Rystiggo | $93 | 6 payments
|
See all 6 published payments
| Ucb | Education · 2025-12-02 | Rystiggo | $15 |
| Ucb | Education · 2025-12-01 | Rystiggo | $15 |
| Ucb | Education · 2025-12-01 | Rystiggo | $15 |
| Ucb | Education · 2025-05-22 | Rystiggo | $15 |
| Ucb | Education · 2025-05-22 | Zilbrysq | $18 |
| Ucb | Education · 2025-03-11 | Rystiggo | $15 |
See earlier years (2019)
2019: $18
| LivaNova USA | Vns Therapy | $18 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1720372576
- Licence
- CA A152405California A152405: Current · expires 2029-02-28
- Trained
- Jefferson Medical College of Thomas Jefferson University, 2011
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2084N0008X (2084N0008X); Neurology (2084N0400X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2011-06-08
- NPI last updated
- 2023-11-10
- NPI record certified
- 2023-11-10
This is when the NPI record was last certified, not a medical board exam.